Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
October 13, 2026
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
September 29, 2026
Cognition Therapeutics to Present at H.C. Wainwright Conference
September 8, 2026
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
August 6, 2026
Cognition Therapeutics Participating in Upcoming Investor Conferences
June 1, 2026
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 7, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
March 17, 2026
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
March 2, 2026